Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis

被引:14
|
作者
Xie, Rujia [1 ]
Deng, Chenhui [1 ]
Wang, Qiang [2 ]
Kanik, Keith S. [2 ]
Nicholas, Timothy [2 ]
Menon, Sujatha [2 ]
机构
[1] Pfizer Inc, Shanghai, Peoples R China
[2] Pfizer Inc, MS 8260-2455,Eastern Point Rd, Groton, CT 06340 USA
关键词
Janus kinase inhibitor; population pharmacokinetics; psoriatic arthritis; tofacitinib; JANUS KINASE INHIBITOR; RECOMMENDATIONS;
D O I
10.5414/CP203516
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This analysis characterized the pharmacokinetics (PK) of tofacitinib in adult patients with active PsA and evaluated the impact of covariates (baseline characteristics) on the disposition of tofacitinib. Materials and methods: Data were pooled from two phase 3 studies of tofacitinib of up to 12 months' duration in patients with active PsA (OPAL Broaden (NCT01877668); OPAL Beyond (NCT01882439)). This analysis included 650 tofacitinib-treated patients with 3,252 tofacitinib plasma concentration measurements. Tofacitinib PK was described using a one-compartment disposition model parameterized in terms of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) with first-order absorption rate (Ka) and a lag time. Covariates evaluated were baseline age, baseline body weight, sex, race, ethnicity, baseline creatinine clearance (BCCL), and baseline C-reactive protein. Results: The estimates (95% confidence interval) of PK model parameters of a reference patient were CL/F: 20.4 (18.6, 21.8) L/h; V/F: 110 (108, 113) L; and Ka: 13.8 (12.1, 16.6)/h. Among the covariates, only BCCL led to clinically relevant changes in exposure; however, this was consistent with the known contribution of renal excretion to the total clearance of tofacitinib (similar to 30%). Conclusion: Tofacitinib did not require dose modification or restrictions for age, body weight, sex, race, ethnicity, or baseline disease severity in patients with active PsA based on the magnitude of exposure relative to a reference patient. Dosing adjustments for renal impairment were derived from a separate phase 1 study.
引用
收藏
页码:464 / 473
页数:10
相关论文
共 50 条
  • [21] EFFECT OF TOFACITINIB ON REDUCING PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Ogdie, A.
    de Vlam, K.
    McInnes, I. B.
    Mease, P. J.
    Baer, P.
    Lukic, T.
    Kwok, K.
    Wang, C.
    Hsu, M. -A.
    Maniccia, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 971 - 972
  • [22] Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis
    Helliwell, Philip S.
    Coates, Laura C.
    FitzGerald, Oliver
    Nash, Peter
    Soriano, Enrique R.
    Husni, M. Elaine
    Hsu, Ming-Ann
    Kanik, Keith S.
    Hendrikx, Thijs
    Wu, Joseph
    Kudlacz, Elizabeth
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [23] EFFICACY OF TOFACITINIB ON DACTYLITIS IN INDIVIDUAL DIGITS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Orbai, A. M.
    Mease, P. J.
    Helliwell, P.
    Fitzgerald, O.
    Bdewi, M.
    Fleishaker, D.
    Mundayat, R.
    Young, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 777 - 778
  • [24] Effect of Tofacitinib on Reducing Pain in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    Ogdie, Alexis
    de Vlam, Kurt
    McInnes, Iain B.
    Mease, Philip J.
    Baer, Philip
    Lukic, Tatjana
    Kwok, Kenneth
    Wang, Cunshan
    Hsu, Ming-Ann
    Maniccia, Anna
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [25] TOFACITINIB IMPROVES COMPOSITE ENDPOINT MEASURES OF DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS
    Helliwell, P.
    Coates, L. C.
    FitzGerald, O.
    Nash, P.
    Soriano, E. R.
    Husni, E.
    Hsu, M-A
    Kanik, K. S.
    Hendrikx, T.
    Wu, J.
    Kudlacz, E.
    [J]. INTERNAL MEDICINE JOURNAL, 2018, 48 : 14 - 15
  • [26] TOFACITINIB IMPROVES COMPOSITE ENDPOINT MEASURES OF DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS
    Helliwell, P.
    Coates, L. C.
    FitzGerald, O.
    Nash, P.
    Soriano, E. R.
    Husni, M. E.
    Hsu, M. -A.
    Kanik, K. S.
    Hendrikx, T.
    Wu, J.
    Kudlacz, E.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 379 - 380
  • [27] Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis
    Orbai, Ana-Maria
    Mease, Philip
    Helliwell, Philip
    FitzGerald, Oliver
    Bedaiwi, Mohamed
    Fleishaker, Dona
    Mundayat, Rajiv
    Young, Pamela
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [28] Analyzing national tofacitinib usage for psoriatic arthritis among Medicare patients
    Desai, Amar D.
    Ahmad, Areebah S.
    Zheng, David X.
    Jabbari, Ali
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB121 - AB121
  • [29] Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib
    Gladman, Dafna
    Tillett, William R.
    Gruben, David
    Coates, Laura
    Hahne, Stefanie
    Volkov, Mikhail
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2802 - 2804
  • [30] TOFACITINIB IMPROVES COMPOSITE ENDPOINT MEASURES OF DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS
    Helliwell, P.
    Coates, L. C.
    FitzGerald, O.
    Nash, P.
    Soriano, E. R.
    Husni, M. E.
    Hsu, M. A.
    Kanik, K. S.
    Hendrikx, T.
    Wu, J.
    Kudlacz, E.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S110 - S110